Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox plus standard treatment in acute myeloid leukemia
IRCT20200313046756N2Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of deferasirox in acute myeloid leukemia (AML) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Rate of apoptotic CD34+ leukemia blasts at day 28, Reactive oxygen species in CD34+ leukemia blasts at day 28 and 1 more. Started Sep 2022; status: completed.
02
Drugs
deferasirox
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20200313046756N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200313046756N2.